The Path Forward: Revealing the Rare Disease Patient Journey
While each rare disease individually impacts only 200,000 people or less, with 7,000 known rare...
In the rapidly evolving world of real-world data (RWD) for life sciences and commercial applications, data provenance and data quality serve as unwavering cornerstones for actionable insights. Yet, an unsettling trend has emerged in the form of "...
While each rare disease individually impacts only 200,000 people or less, with 7,000 known rare...
As life settles into the new normal after the worst of the COVID-19 pandemic, it is clear that...
While it feels like we’re back to a pre-pandemic sense of normal, COVID continues to be an evolving...
With the surge in RSV cases that plagued our nation’s children at record levels this fall and over...
The challenges of the COVID-19 pandemic did bring about some positive impact, accelerating the...
Historically, clinical trial data and real-world data (RWD) have existed in silos. With increasing...
A recent survey by the Deloitte Center for Health Solutions of biopharma executives and other...
Diabetes is a complex disease that affects over 37 million Americans, or 11% of the population, and...
As we honor our military service members this Veterans Day, we take time to reflect on how we can...
In a recent report, the Centers for Disease Control and Prevention (CDC) found that four out of...
Traditional data aggregators are not enough The pharmaceutical industry is hitting a wall. Data aggregators, once considered reliable partners, are now liabilities facing significant challenges, including cyber threats, data restrictions, and opaque ...